Ryan Patel

Healthcare & Life Sciences Analyst

Drug pipelines, FDA catalysts, and biotech valuation. Came from equity research at Jefferies covering mid-cap pharma. His analysis tends to be contrarian — he'll downgrade a consensus favorite if the Phase 3 data doesn't hold up to scrutiny.